Početna › Kronična limfocitna leukemija › Oregon
Kliničke studije za Kronična limfocitna leukemija u državi Oregon
16 studija za Kronična limfocitna leukemija traži sudionike na lokacijama u državi Oregon.
Gradovi u državi Oregon
Službeni tekst studije (engleski)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- i još 1
U tijeku regrutacijaFaza 3
Od 65 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- i još 7
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Saint Charles Health System, Bend
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06846671A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Oregon Health and Science University ( Site 5425), Portland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT05947851Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT06784167A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Portland
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT06564038Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Oncology Associates of Oregon, Eugene
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07520006Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Williamette Valley Cancer Institute & Research Center, Eugene
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 19. svi 2026. · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Willamette Valley Cancer Institute and Research Center /ID# 266326, Eugene
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. tra 2026. · NCT06428019Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- OHSU Knight Cancer Institute, Portland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 6. stu 2025. · NCT05943496A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2025. · NCT05780034Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.